| Date | Title | Description |
| 20.02.2026 | What is ALS, the disease that killed actor Eric Dane? | Getting your Trinity Audio player ready...
By LAURA UNGAR
Eric Dane, known for his roles on “Grey’s Anatomy” and “Euphoria,” died this week from amyotrophic lateral sclerosis at age 53. Related Articles
Work begins on cleanup of Nederland f... |
| 04.04.2024 | Relyvrio ALS Drug Withdrawn by Manufacturer Due to Lack of Efficacy | Quincy Jon, Tech Times 04 April 2024, 02:04 pm
Amylyx Pharmaceuticals removed a Lou Gehrig's disease, also known as amyotrophic lateral sclerosis (ALS), medication from the market on Thursday, Apr. 11. The move comes after extensive researc... |
| 13.03.2024 | Investors Beware: Class Action Lawsuits Target GrafTech, Instacart, Cassava, and Amylyx | Bragar Eagel & Squire, P.C. is on the hunt for justice as they remind investors of the ongoing class action lawsuits against GrafTech, Instacart, Cassava, and Amylyx. These companies are under fire, and investors need to stay informed a... |
| 13.03.2024 | Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman | - |
| 12.03.2024 | How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay? | Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements.
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral ... |
| 12.03.2024 | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm | - |
| 12.03.2024 | AMLX LAWSUIT ALERT: The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | - |
| 12.03.2024 | How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay? | - |
| 11.03.2024 | Kirby McInerney LLP Reminds Investors of Lead Plaintiff Deadline in Amylyx Pharmaceuticals, Inc. (AMLX) Securities Class Action | - |
| 11.03.2024 | ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX | NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November 11, 2022 and November 8, 2023, both dates ... |
| 10.03.2024 | AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | - |
| 08.03.2024 | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm | - |
| 07.03.2024 | ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX | - |
| 07.03.2024 | DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline | - |
| 07.03.2024 | Amylyx Pharmaceuticals Class Action: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline | - |
| 09.11.2023 | Eli Lilly tries a rare tactic: competing on price | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a counterintuitive idea in pharma, an ode to scientific matrimony, and the ... |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders
Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 30.09.2022 | A controversial new drug to treat ALS just got approved by the FDA. Analysts say the decision could also benefit these 8 other companies. | (right to left) Joshua Cohen and Justin Klee, the cofounders and co-CEOs of Amylyx Pharmaceuticals. Amylyx This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Amylyx's drug Relyvri... |
| 26.09.2022 | A controversial ALS drug potentially worth $1 billion is on the cusp of FDA approval. It could change Amylyx's fortunes and be a much-needed treatment for the rare disease. | (left to right) Joshua Cohen and Justin Klee, the cofounders and co-CEOs of Amylyx Pharmaceuticals. Amylyx This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
The FDA may soon appr... |
| 08.09.2022 | In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in 2nd Review
Was this page helpful? | THURSDAY, Sept. 8, 2022 (HealthDay News) – In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for ALS (amyotrophic lateral sclerosis).
The FDA is not obligated to fo... |
| 06.09.2022 | FDA Panel Skeptical of Controversial ALS Drug Ahead of Vote | TUESDAY, Sept. 6, 2022 (HealthDay News) -- A U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for amyotrophic lateral sclerosis (ALS), a rare second review for a disease that has no cure.
Th... |
| 06.09.2022 | FDA Panel Skeptical of Controversial ALS Drug Ahead of Vote
Was this page helpful? | TUESDAY, Sept. 6, 2022 (HealthDay News) – A U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for ALS, a rare second review for a disease that has no cure.
The same panel that will meet Wedne... |
| 16.08.2022 | As a pediatric cancer researcher, I admired the FDA. Then I got ALS | Amyotrophic lateral sclerosis (ALS), as I have unfortunately come to learn, is a terrible disease with no cure. Some exciting treatments are on the horizon, but the Food and Drug Administration’s Office of Neuroscience, which has the task o... |
| 13.06.2022 | New ALS Drug Approved in Canada While Still Under FDA Review | MONDAY, June 13, 2022 (HealthDay News) -- An experimental drug for the neurological disorder ALS was approved in Canada on Monday, but an ongoing evaluation of the treatment by the U.S. Food and Drug Administration has raised questions abou... |
| 13.06.2022 | New ALS Drug Approved in Canada While Still Under FDA Review | MONDAY, June 13, 2022 (HealthDay News) -- An experimental drug for amyotrophic lateral sclerosis (ALS) was approved in Canada on Monday, but an ongoing evaluation of the treatment by the U.S. Food and Drug Administration has raised question... |
| 21.04.2022 | Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy? | On March 30, an FDA advisory panel voted 6 to 4 against recommending approval of what might be the most effective treatment to date for amyotrophic lateral sclerosis. The panel’s decision is not binding, and the FDA could disregard its reco... |
| 07.01.2022 | Amylyx Pharma’s IPO lands $190M as ALS drug begins FDA review | Amylyx Pharmaceuticals has joined the public markets with a $190 million IPO that will support the company as it shepherds its amyotrophic lateral sclerosis drug through regulatory review, and if all goes well, a commercial launch as a new ... |
| 21.07.2021 | Why did crypto exchange Binance exit FTX? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content Why Deloitte is making a call for innovation now From Deloitte
Sam Bankman-Fried has... |
| 21.07.2021 | Why did crypto exchange Binance exit FTX? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content Why today's marketers need strong collaboration tools From Optimizely
Sam Bankman-Fr... |
| 20.07.2021 | Amylyx Pharmaceuticals Closes $135M Series C Financing Led by Viking Global Investors to Support Late Stage Development of Lead Product Candidate AMX0035 for the Treatment of ALS | Amylyx Pharmaceuticals, Inc. today announced the closing of an oversubscribed $135 million Series C financing, led by Viking Global Investors, to support the clinical development and potential launch plans for lead product candidate AMX0035... |
| 20.07.2021 | Amylyx Pharmaceuticals Inks $135M Series C |
CAMBRIDGE, MA, Amylyx Pharmaceuticals today announced the closing of an oversubscribed $135 million Series C financing.
>> Click here for more funding data on Amylyx Pharmaceuticals
>> To export Amylyx Pharmaceuticals fundin... |
| 20.07.2021 | Amylyx Pharmaceuticals Raises $135M in Series C Financing | Amylyx Pharmaceuticals, Inc., a Cambridge, MA-based pharmaceutical company, closed $135m in Series C financing.
The round was led by Viking Global Investors, with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Spri... |
| 20.07.2021 | Amylyx raises $135M to gear up for potential Canadian launch of ALS drug | A month after filing for Canadian approval for its lead ALS candidate, Amylyx Pharmaceuticals has picked up $135 million to bankroll a potential commercial launch and support a pipeline of other candidates for neurodegenerative diseases, in... |
| 20.07.2021 | Amylyx Pharmaceuticals raises $135M as ALS drug heads to pivotal clinical trial | Amylyx Pharmaceuticals showed in a clinical trial that its amyotrophic lateral sclerosis (ALS) drug slowed the muscle-wasting disease’s progression. The drug is now being readied for a larger, pivotal study aiming to replicate those results... |
| 22.06.2021 | FDA should lead the way on new ALS treatments, not Canada and Europe | Following the Food and Drug Administration’s recent decision to give the green light to aducanumab, the first treatment approved for Alzheimer’s disease in nearly two decades, the agency has been loudly criticized by some for moving too qui... |
| 11.05.2021 | Fast-Growing Network Life Science Platform Company, Eagle Genomics, Adds 3 New US Advisory Board Members to its Global Panel | The successful British scale-up has attracted senior figures in international business development, pharmaceutical commercial strategy and nutrition innovation in San Diego, Cambridge Massachusetts, and New York to help shape the next phase... |
| 01.07.2020 | Amylyx Pharmaceuticals Raises $30M in Series B |
CAMBRIDGE, MA, Amylyx Pharmaceuticals has closed an oversubscribed $30 million Series B financing, led by Morningside Ventures.
>> Click here for more funding data on Amylyx Pharmaceuticals
>> To export Amylyx Pharmaceutical... |
| 01.07.2020 | Amylyx Pharmaceuticals Raises $30 Million in Series B Funding | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announce... |
| 22.08.2016 | Amylyx Raises $5 Million Series A | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Inc. announced today that it has completed a $5 million Series A financing to support its upcoming Phase II trial in patients with Amyotrophic Lateral Sclerosis (ALS). Morningside Ve... |
| 22.08.2016 | Amylyx Raises $5M in Series A Funding | Amylyx Pharmaceuticals Inc., a Cambridge, MA-based developer of a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, raised $5m in Series A Funding.
The round was led by Morningside Venture with ... |
| 17.11.2015 | Amylyx gets $1.9M for ALS, Alzheimer’s drug that mediates organelle stress | “The ALS Finding a Cure Foundation is committed to pursuing multiple avenues toward a cure for ALS,” Merit Cudkowicz, the foundation’s chief medical officer as well as chief of neurology at Massachusetts General Hospital, said in a statemen... |
| - | Amylyx Pharmaceuticals raises $135M as ALS drug heads to pivotal clinical trial | Amylyx Pharmaceuticals showed in a clinical trial that its amyotrophic lateral sclerosis (ALS) drug slowed the muscle-wasting disease’s progression. The drug is now being readied for a larger, pivotal study aiming to replicate those results... |
| - | Amylyx Pharma’s IPO lands $190M as ALS drug begins FDA review | Amylyx Pharmaceuticals has joined the public markets with a $190 million IPO that will support the company as it shepherds its amyotrophic lateral sclerosis drug through regulatory review, and if all goes well, a commercial launch as a new ... |
| - | Amylyx gets $1.9M for ALS, Alzheimer’s drug that mediates organelle stress | Cambridge startup Amylyx Pharmaceuticals is developing a new combination drug product that could help treat neurodegenerative diseases like ALS, Alzheimer’s disease and mitochondrial disorders.
It just raised $1.3 million in a new equity ro... |
